334 related articles for article (PubMed ID: 19721826)
1. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Shin SW
Korean J Radiol; 2009; 10(5):425-34. PubMed ID: 19721826
[TBL] [Abstract][Full Text] [Related]
2. [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results].
Vogl TJ; Zangos S; Balzer JO; Nabil M; Rao P; Eichler K; Bechstein WO; Zeuzem S; Abdelkader A
Rofo; 2007 Nov; 179(11):1113-26. PubMed ID: 17948190
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.
Miraglia R; Pietrosi G; Maruzzelli L; Petridis I; Caruso S; Marrone G; Mamone G; Vizzini G; Luca A; Gridelli B
World J Gastroenterol; 2007 Jun; 13(21):2952-5. PubMed ID: 17589945
[TBL] [Abstract][Full Text] [Related]
4. Palliative treatment of hepatocellular carcinoma by chemoembolization.
Poyanli A; Rozaneş I; Acunaş B; Sencer S
Acta Radiol; 2001 Nov; 42(6):602-7. PubMed ID: 11736709
[TBL] [Abstract][Full Text] [Related]
5. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
Kim JH; Kim PN; Won HJ; Shin YM
AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
Kang JW; Kim JH; Ko GY; Gwon DI; Yoon HK; Sung KB
Acta Radiol; 2012 Jun; 53(5):545-50. PubMed ID: 22547388
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
8. Effect of preoperative transcatheter arterial chemoembolization on proliferation of hepatocellular carcinoma cells.
Xiao EH; Li JQ; Huang JF
World J Gastroenterol; 2007 Sep; 13(33):4509-13. PubMed ID: 17724810
[TBL] [Abstract][Full Text] [Related]
9. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
10. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.
Chia-Hsien Cheng J; Chuang VP; Cheng SH; Lin YM; Cheng TI; Yang PS; Jian JJ; You DL; Horng CF; Huang AT
Int J Cancer; 2001 Aug; 96(4):243-52. PubMed ID: 11474499
[TBL] [Abstract][Full Text] [Related]
11. Chemoembolization agents for cancer treatment.
Tam KY; Leung KC; Wang YX
Eur J Pharm Sci; 2011 Sep; 44(1-2):1-10. PubMed ID: 21726636
[TBL] [Abstract][Full Text] [Related]
12. Current concepts in transarterial chemoembolization of hepatocellular carcinoma.
Huppert P
Abdom Imaging; 2011 Dec; 36(6):677-83. PubMed ID: 21674193
[TBL] [Abstract][Full Text] [Related]
13. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
[TBL] [Abstract][Full Text] [Related]
14. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.
Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI
Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020
[TBL] [Abstract][Full Text] [Related]
15. Ultraselective conventional transarterial chemoembolization: When and how?
Miyayama S
Clin Mol Hepatol; 2019 Dec; 25(4):344-353. PubMed ID: 31022779
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection.
Eguchi S; Matsumoto S; Hamasaki K; Takatsuki M; Hidaka M; Tajima Y; Sakamoto I; Kanematsu T
J Hepatobiliary Pancreat Surg; 2008; 15(6):627-33. PubMed ID: 18987934
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.
Molinari M; Kachura JR; Dixon E; Rajan DK; Hayeems EB; Asch MR; Benjamin MS; Sherman M; Gallinger S; Burnett B; Feld R; Chen E; Greig PD; Grant DR; Knox JJ
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization of hepatic malignancy.
Gonsalves CF; Brown DB
Abdom Imaging; 2009; 34(5):557-65. PubMed ID: 18668189
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 May; 10(5):679-90. PubMed ID: 23406440
[TBL] [Abstract][Full Text] [Related]
20. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
